GERON CORP cotiza a 1.22 USD y tiene una capitalización bursátil de $784M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-depend…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.02 | — | $-0.02 |
| Estimado | $-0.01 | $-0.01 | $-0.02 | $-0.04 |
| Sorpresa | — | -100.0% | — | +50.0% |
| Métrica | GERN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -37.0% | -40.4% | +3.4% |
| ROA | -14.6% | -32.0% | +17.4% |
| Current Ratio | 4.66 | 2.84 | +1.82 |
| Debt / Equity | 0.53 | 0.28 | +0.25 |